Ancrod

What is Ancrod?

Ancrod is a unique pharmaceutical ingredient classified as a fibrinolytic enzyme. Derived from the venom of the Malayan pit viper (Calloselasma rhodostoma), it acts as a powerful defibrinogenating agent. Historically, Ancrod has been utilized in specialized anticoagulant therapy to reduce the viscosity of blood and improve microcirculation. Unlike many conventional anticoagulants, Ancrod's primary mode of action is to specifically degrade fibrinogen, a key protein involved in blood clot formation, rather than directly inhibiting coagulation factors.

Its discovery and development marked a significant step in understanding fibrinolysis and offered an alternative approach to managing thrombotic conditions. While its use has become less common with the advent of newer anticoagulants, Ancrod remains a fascinating compound with a distinct pharmacological profile, offering insights into the complex processes of blood clotting and its therapeutic modulation.

How Does it Work?

The mechanism of action of Ancrod is distinct and highly specific. Upon administration, Ancrod acts as a thrombin-like enzyme, directly cleaving fibrinogen (factor I) at specific sites, primarily the Aα-chain. This enzymatic action results in the formation of an abnormal fibrin monomer, which is structurally different from the fibrin monomers produced by thrombin. These Ancrod-induced fibrin monomers are less stable and form a weak, easily degradable clot structure, or they are rapidly cleared from the circulation by the reticuloendothelial system before they can polymerize effectively.

The rapid removal of fibrinogen from the blood by Ancrod leads to a profound and sustained reduction in circulating fibrinogen levels, often by 80-90% within hours. This state of hypofibrinogenemia effectively renders the blood incoagulable, as the essential substrate for clot formation is drastically reduced. Furthermore, Ancrod has been shown to reduce blood viscosity and may also inhibit platelet aggregation to some extent, contributing to its overall antithrombotic effects. Its action is not reversed by protamine sulfate, unlike heparin, making its management unique in clinical settings.

Medical Uses

Ancrod has been investigated and used for various medical conditions where a reduction in blood viscosity and prevention of clot formation are critical. Its primary application has been in conditions requiring rapid defibrinogenation. Historically, it was used in the management of:

• Deep Vein Thrombosis (DVT)

  Ancrod was employed to prevent and treat deep vein thrombosis, particularly in patients who could not tolerate conventional anticoagulants or required a rapid onset of action.

• Peripheral Arterial Occlusive Disease

  By reducing blood viscosity and improving microcirculation, Ancrod was used to alleviate symptoms and improve blood flow in patients with severe peripheral arterial disease.

• Acute Ischemic Stroke

  In some studies, Ancrod was explored as a treatment for acute ischemic stroke, with the aim of reducing clot burden and improving cerebral blood flow to salvage penumbral tissue. Its role here was controversial and largely superseded by thrombolytic agents like tPA.

• Priapism

  Due to its ability to reduce blood viscosity and dissolve microthrombi, Ancrod has also been used in specific cases of priapism.

While the widespread clinical use of Ancrod has diminished due to the availability of newer, often more manageable anticoagulants and antithrombotic agents, it remains a valuable tool in specific, specialized settings or as a research compound. Its unique mechanism of action makes it a subject of ongoing interest for conditions where conventional anticoagulants may not be ideal.

Dosage

The administration of Ancrod typically involves intravenous infusion, and the dosage is carefully titrated to achieve and maintain specific target levels of fibrinogen in the blood. Due to its potent effect on blood coagulation, Ancrod therapy requires stringent medical supervision and frequent monitoring of coagulation parameters, particularly fibrinogen levels.

• Initial Dose

  A typical initial loading dose might be administered over several hours to rapidly reduce fibrinogen levels. This phase aims to achieve a therapeutic hypofibrinogenemic state, often targeting fibrinogen levels below 0.2 g/L.

• Maintenance Dose

  Following the initial dose, a continuous intravenous infusion or intermittent boluses are used as a maintenance dose to sustain the reduced fibrinogen levels. The exact dose will depend on the patient's response, body weight, and the desired therapeutic effect.

• Monitoring

  Regular monitoring of plasma fibrinogen levels is crucial to guide dosage adjustments and ensure patient safety. Other coagulation parameters, such as prothrombin time (PT) and activated partial thromboplastin time (aPTT), may also be monitored, although Ancrod's primary effect is directly on fibrinogen.

It is imperative that Ancrod is administered only by healthcare professionals experienced in its use and in facilities equipped to manage potential complications, especially bleeding.

Side Effects

As a powerful anticoagulant therapy, the most significant and common side effect of Ancrod is bleeding. The risk of bleeding is directly related to the reduction in fibrinogen levels and can range from minor ecchymoses to severe, life-threatening hemorrhages. Patients receiving Ancrod must be closely monitored for any signs of bleeding.

• Common Side Effects

  • Bleeding: This is the most prevalent adverse effect and can manifest as epistaxis (nosebleeds), hematuria (blood in urine), gastrointestinal bleeding, or bleeding from injection sites.
  • Local Reactions: Pain, swelling, or redness at the infusion site.

• Less Common or Severe Side Effects

  • Allergic Reactions: Although rare, some individuals may experience hypersensitivity reactions, including rash, itching, or, in severe cases, anaphylaxis.
  • Hypotension: A drop in blood pressure has been reported in some patients.
  • Headache and Nausea: Non-specific symptoms that may occur during treatment.
  • Thrombocytopenia: A decrease in platelet count, although less common than with other anticoagulants.

Due to the risk of bleeding, Ancrod is contraindicated in patients with active bleeding, severe hypertension, recent surgery involving the central nervous system or eyes, and conditions predisposing to hemorrhage. Careful patient selection and vigilant monitoring are essential to minimize risks.

Drug Interactions

The use of Ancrod in conjunction with other medications that affect blood coagulation or platelet function can significantly increase the risk of bleeding. Healthcare providers must be aware of all concomitant medications when prescribing Ancrod.

• Other Anticoagulants

  Concomitant use with other anticoagulants such as heparin, warfarin, or direct oral anticoagulants (DOACs) can potentiate the anticoagulant effect and dramatically increase the risk of hemorrhage.

• Antiplatelet Agents

  Drugs that inhibit platelet aggregation, including aspirin, clopidogrel, prasugrel, ticagrelor, and NSAIDs (non-steroidal anti-inflammatory drugs), can enhance the bleeding risk when used with Ancrod.

• Thrombolytic Agents

  The combined use of Ancrod with thrombolytic drugs (e.g., alteplase, streptokinase) is generally contraindicated due to an extremely high risk of severe bleeding.

• Drugs Affecting Blood Viscosity

  While Ancrod itself reduces blood viscosity, care should be taken with other agents that might influence this parameter, though direct interactions are less well-defined.

Patients should always inform their healthcare provider about all medications, supplements, and herbal remedies they are taking to avoid potentially dangerous drug interactions.

FAQ

Is Ancrod still used in clinical practice today?

While its widespread use has diminished in favor of newer anticoagulants, Ancrod is still used in specific, specialized clinical situations or as a research tool where its unique defibrinogenating properties are particularly advantageous. Its application is typically reserved for expert centers.

What is the primary risk associated with Ancrod treatment?

The most significant risk associated with Ancrod is bleeding, ranging from minor to severe hemorrhage. This is due to its potent effect on reducing blood fibrinogen levels, which impairs the blood's ability to clot.

How is Ancrod administered?

Ancrod is typically administered via intravenous infusion, with the dosage carefully adjusted based on the patient's response and monitored fibrinogen levels.

Is Ancrod derived from snake venom?

Yes, Ancrod is an enzyme isolated from the venom of the Malayan pit viper (Calloselasma rhodostoma).

How quickly does Ancrod reduce fibrinogen levels?

Ancrod can rapidly reduce plasma fibrinogen levels, often by 80-90% within hours of administration, leading to a state of therapeutic hypofibrinogenemia.

Products containing Ancrod are available through trusted online pharmacies. You can browse Ancrod-based medications at ShipperVIP or Medicenter.

Summary

Ancrod is a unique and potent defibrinogenating agent derived from snake venom, distinct from other anticoagulants in its mechanism of action. By directly cleaving fibrinogen, it rapidly and significantly reduces the blood's ability to form clots, making it effective in conditions requiring rapid anticoagulation or reduction of blood viscosity. While its historical uses included the treatment of deep vein thrombosis, peripheral arterial disease, and stroke treatment, its current clinical application is more specialized. The primary concern with Ancrod therapy is the risk of bleeding, necessitating careful patient selection, meticulous dosage titration, and continuous monitoring of fibrinogen levels. Despite the availability of newer antithrombotic agents, Ancrod remains a valuable compound for specific indications and continues to contribute to our understanding of hemostasis and thrombosis.